Skip to main content

Table 1

From: Excellent short-term CD4 recovery with a PI- and NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirine

 

N

BL HIV-RNA

BL CD4

W24 CD4

Group A: RAL+MVC+ETR

15

4.2(3.9–5.1)

276(90–528)

552(398–718)

Group B: RAL + MVC or ETR + PI sparing OBT**

17

4.0(3.9–4.7)

197(94–295)

378(330–447)

Group C: RAL + MVC or ETR +PI/r* based OBT**

20

4.7(3.8–5.3)

160(63–198)

306(239–361)

Group D: RAL + PI/r* based OBT**

16

4.2(3.6–4.9)

240(121–329)

349(276–504)

  1. *in 33/36 darunavir/r **OBT = optimized background therapy.